Scott Kopetz, MD, PhD | Authors


Updated Survival Data from BEACON CRC Lead to More Specific Questions

June 02, 2020

Scott Kopetz, MD, PhD, discusses the next steps following the phase 3 BEACON CRC trial of encorafenib plus cetuximab with or without binimetinib compared with irinotecan or FOLFIRI plus cetuximab in patients with BRAF V600E metastatic colorectal cancer.

Differences in Prognoses for Patients With Right-Sided or Left-Sided Colorectal Cancer

October 25, 2019

Scott Kopetz, MD, PhD, explains how prognoses for patients with colorectal cancer differ based on whether their cancer is left-sided or right-sided and discusses how knowledge of these differences have led to the development of more agents to treat both groups of patients.